Perrigo Company

  • Is This Healthcare Stock Underrated?

    By Leo Sun - August 16, 2013 | Tickers: ELN, GSK, JNJ, PRGO, TEVA

    Shares of Perrigo Company (NYSE: PRGO), one of the world’s largest healthcare suppliers, slid with the broader market on August 15, after the company reported fourth quarter earnings that topped analyst estimates but missed revenue forecasts. Over the past month, Perrigo has drawn a lot of criticism for its $8.6 billion takeover of Irish pharmaceutical Elan Corporation (NYSE: ELN), which redcued its corporate tax rate by moving its more »

  • Why I Like Generic Pharmaceuticals

    By Daniel Jennings - August 12, 2013 | Tickers: RDY, MYL, PRGO

    I don’t like traditional pharmaceutical houses as either a business or an investment. I think the way they try to gouge customers with no choice—sick people—with high prices is just plain wrong. The high research and development costs, sleazy marketing practices, and abuse of the patent system to needlessly jack up prices put me off.

    Yet there’s one area of the drug business I like: generic more »

  • Obamacare and Generic Pharmaceuticals

    By Daniel Jennings - August 9, 2013 | Tickers: ACT, PRGO, TEVA

    Will generic pharmaceutical makers like Teva Pharmaceutical (NYSE: TEVA) and Perrigo (NYSE: PRGO) continue to be a value play after Obamacare kicks in next year?

    That’s a fair question to ask because some of these companies seem to be on shaky ground now. Revenues and free cash flow have been falling without Obamacare.

    <img alt="" src="" />

    Teva saw its revenues fall by 8% in the fourth quarter of 2012 and a pretty more »

  • This Deal Could Shake Up the Generic Drug Business

    By Mike Thiessen - August 8, 2013 | Tickers: ACT, ELN, PRGO

    Many market-watchers are scratching their heads about the pharmaceutical industry's latest blockbuster deal. Although it had been expected to make such a move for some time, Perrigo Company (NYSE: PRGO) is not regarded as the "ideal" buyer for Dublin-based Elan (NYSE: ELN). Both firms operate as generic drug-makers, but the synergies between the two are not immediately obvious. 

    Moreover, Elan is coming off of a long, painful battle to more »

  • Will This Be the Next Irish Biotech Acquisition?

    By Brian Nichols - August 7, 2013 | Tickers: ELN, JAZZ, PRGO

    Perrigo Company’s (NYSE: PRGO) acquisition of Elan (NYSE: ELN) for $8.6 billion has been widely criticized by many as a way for Perrigo to avoid paying a high U.S. corporate tax rate. Analysts believe that Perrigo’s acquisition represents a shift where companies are seeking assets in low taxed countries to increase profitability. According to analysts, there were several companies that were bidding to acquire Elan, but more »

  • This Merger Adds Value Multiple Ways

    By Mohsin Saeed - August 5, 2013 | Tickers: ELN, PRGO, PG

    2013 is turning out to be a stellar year for Mergers and Acquisitions. There have been a number of M&A deals in healthcare and technology sectors. Technology sectors might be in the news more often, but it’s the healthcare sector which has the highest number of M&As. During the current year, there have already been 426 confirmed deals. There were 203 M&As in the first quarter more »

  • Examining an Acquisition That Benefits This Global Healthcare Supplier

    By Anh HOANG - August 5, 2013 | Tickers: BIIB, ELN, PRGO

    Recently, Elan Corporation (NYSE: ELN) ended the fight against bids from Royalty Pharma. Previously, Royalty Pharma had raised its all-cash offer from $5.7 billion to $6.4 billion. Elan still thinks that Royalty Pharma’s offer continued to “grossly undervalue its current business platform and its future prospects, however. Instead, Elan went for an $8.6 billion offer of Perrigo Company (NYSE: PRGO).

    Perrigo’s business snapshot

    Perrigo has more »

  • Is This Acquisition a Game Changer?

    By Awais Iqbal - August 5, 2013 | Tickers: ACT, ELN, PRGO

    A patented drug is a cash cow for drug manufacturers. There are two ways to have a patented cash generating drug on a pharmaceutical company’s pipeline. Either conduct research and organically develop the medicine, or acquire a company with a strong pipeline. The latter option is what Perrigo (NYSE: PRGO) recently opted for by acquiring Elan (NYSE: ELN). Additionally, Perrigo looks forward to increasing its international presence with this more »

  • Should Companies Use Acquisitions and Financial Engineering to Reduce Corporate Taxes?

    By Leo Sun - August 2, 2013 | Tickers: ACT, AAPL, ELN, PRGO, WCRX

    Perrigo (NYSE: PRGO), an American company best known for selling generic medication, baby formula and nutritional supplements, recently acquired Irish drugmaker in Elan (NYSE: ELN) for $8.6 billion in an unexpected deal that initially left investors puzzled. After all, what would Perrigo gain by acquiring Elan, a biotech primarily focused on experimental treatments for neurodegenerative and autoimmune diseases? The answer was simple - lower tax rates.

    A big buy for more »

  • Three Unique Medical Niche Companies

    By Reuben Brewer - May 28, 2013 | Tickers: LDR, PRGO, SRCL

    The health care industry in The United States is going through a major period of transformation. There are some companies that have such unique niches, however, that they will handle any changes in stride. Investors should take a look at specialty players Stericycle (NASDAQ: SRCL), Landauer (NYSE: LDR), and Perrigo (NYSE: PRGO).

    Still Fighting

    Obamacare hasn't taken full effect. While lawmakers continue to debate the law, the industry and more »

  • Good News For Health Care Stocks Part 2

    By Reuben Brewer - May 17, 2013 | Tickers: JNJ, PRGO, TEVA

    It isn't surprising that providing Medicaid coverage to lower-income residents of Oregon led to an increased use of health care services. However, taking that finding a step further can lead to some interesting investing ideas.

    The Oregon Study

    The New England Journal of Medicine recently released the results of the Oregon Study. That research tracked Oregon's test of randomly assigning lower-income adults into a group that received Medicaid more »

  • 3 Healthcare Picks From Janus Fund

    By Reuben Brewer - April 30, 2013 | Tickers: ESRX, PRGO, VRTX

    Janus Fund (JANDX) bares the name of the fund family behind it. The flagship offering focuses on growth. Three healthcare stocks that underperformed for the fund in 2012 still appear to have growth potential.


    Janus Fund focuses on growth. In its search for companies with “earnings growth potential that may not be recognized by the market at large,” management starts at the ground floor. Building its research and portfolio more »

  • Scared of a Market Fall? Watch These Defensive Growth Stocks

    By Lee Samaha - April 29, 2013 | Tickers: AGN, CHD, PRGO, COO, TJX

    The market turbulence in April has left many if whether we are headed for another spring sell off. I have no opinion on this, per se, but what I do know is that it always makes sense for investors to try and be diversified. So if you are worried about the economy or just looking to create a balanced portfolio, the following stocks should be of interest.

    Defensive growth

    I more »

  • Landmark Judgment Could Give These Stocks a Boost

    By Jacob Wolinsky - April 12, 2013 | Tickers: ACT, PRGO, TEVA

    A federal judge in Brooklyn, New York, has ruled that the morning-after pill (levonorgestrel) used as an emergency contraceptive will now be available over the counter with no age restrictions.

    Judge Edward Korman’s ruling effectively overturned a previous decision by the Secretary of Health and Human Services, as it was considered to be "arbitrary, capricious, and unreasonable" by Korman. The previous decision urged the FDA to reject a petition more »

  • Strong Long Term Prospects With This Defensive Growth Play

    By Lee Samaha - February 19, 2013 | Tickers: CVS, JNJ, PRGO, WAG

    Perrigo (NYSE: PRGO) is a company exposed to some very favorable trends in health care, and I would expect its strong performance to continue. In summary, while I have little doubts over its end markets or its growth, the evaluation looks stretched, and there are some near term risks here. Unfortunately, the defensive growth sector (if such a thing exists) has been bid up by the market, and I think more »

  • "Stock Market Joe"

    By Gerelyn Terzo - February 8, 2013 | Tickers: PRGO, PFE, ZTS

    In Super Bowl XLVII, Baltimore Ravens' rookie quarterback Joe Flacco led the team to victory and to recapture a title that has eluded the organization for more than a decade. One of the Super Bowl sports commentators on the CBS Network referred to the Super Bowl MVP as "stock market Joe" because as Joe -- who had highs and lows in the season -- was gearing his team up for victory, so more »

  • TARO Continues to Post Strong Results

    By John A - February 8, 2013 | Tickers: PRGO, TARO, TEVA, VRX

    Read, understand and consent to the blog's DISCLAIMER here before proceeding to read the article

    Taro Pharmaceutical (NYSE: TARO) is an interesting developing story. I continue to believe that TARO's market value is significantly higher than what is reflected in today's market price. TARO's market price is effectively capped from appreciation due to a number of reasons including the pending $39.50 offer from the majority more »

  • A Look at the Best Performing Stocks Since the Market's All-Time High

    By Brian Nichols - February 1, 2013 | Tickers: NFLX, PRGO, PCLN, REGN, ROST

    On October 7, 2007 the Dow Jones closed at a record 14,164.53. Obviously we have traded lower since that point, but are quickly approaching several psychological milestones that include new all-times highs. In theory, a stock that has traded with any level of gains since October 2007 has outperformed the market and has been a good investment. But what are the best investments since October 2007, and can more »

  • What’s Moving These Biotechs?

    By Brian Nichols - January 14, 2013 | Tickers: FOLD, DNDN, PRGO, TSPT

    A number of biotechs of all sizes saw significant price action last week, specifically on Friday. It wasn’t just gainers that made the headlines, but also stocks seeing a significant decline. Therefore, I am looking at the best and worst, performing biotechs to determine what moved them and how to play the movement.

    Dendreon (NASDAQ: DNDN)

    Dendreon is probably the most controversial biotech stock in the market, due to more »

  • Why I'm Not Convinced by This Pharma Company's Latest Presentation

    By Lee Samaha - January 7, 2013 | Tickers: CVS, MJN, PRGO, WMT, WAG

    The JP Morgan Healthcare conference is the most important event on the industry's calendar and helps set the tone for the rest of the investing year. Typically the pharma/biotech companies outline the key pipeline events of the year or how they plan to expand existing product sales while the medical technology and services companies discuss their prospects for the coming year. I thought I’d help investors compress more »

  • Page 1 of 2